Tafamidis ATTR denied as duplicate or overlapping therapy by Humana?

Humana's specific coverage criteria for tafamidis attr are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana May Deny Tafamidis as "Duplicate Therapy" — and Why This Denial Is Usually Wrong

A duplicate-therapy denial means Humana's system identified another active claim or dispensed drug it considers therapeutically equivalent to tafamidis. In ATTR cardiomyopathy, this denial is almost always a pharmacy system artifact: tafamidis is the only approved transthyretin stabilizer in its class, so there is no true duplicate. The "duplicate" flagged is commonly a heart failure drug (a diuretic, beta-blocker, or ACE inhibitor) that Humana's drug-interaction or therapeutic-category algorithm incorrectly grouped with tafamidis. These denials resolve quickly once the clinical distinction is documented.

## Your Federal Appeal Rights

• ACA §2719 External Review: If Humana's internal review upholds the denial, you may request independent external review within approximately four months of the final internal denial notice — check your Explanation of Benefits for the precise date.
• ERISA §503: Employer-plan members are entitled to the specific drug and therapeutic category Humana identified as duplicative, written clinical rationale, and a full-and-fair review.
• Expedited Track: Available if clinical urgency warrants; typically resolved within 72 hours of request.

## Concrete Appeal Steps and Timeline

1. Request from Humana the name of the drug it considers duplicative of tafamidis. 2. Have the prescriber write a brief letter explaining the mechanism difference between tafamidis (transthyretin tetramer stabilizer) and the flagged drug — this distinction is the entire appeal. 3. File a Level 1 internal appeal with that letter attached alongside the FDA-approved prescribing information confirming tafamidis's unique indication. 4. If denied internally, escalate to external IRO review within the deadline. 5. Also contact the dispensing pharmacy — some duplicate edits are resolvable at the pharmacy benefit manager level without a formal appeal.

## Documentation to Gather

• Name of the alleged duplicate: Obtain this from the denial letter or by calling Humana.
• FDA prescribing information for tafamidis: The "Indications and Usage" and "Mechanism of Action" sections establish that no other approved drug shares this mechanism in ATTR-CM.
• Current medication list: A reconciled list from the prescriber demonstrating that each other cardiac drug serves a distinct therapeutic purpose.
• Prescriber letter: Concisely explains why concurrent use of the flagged drug does not constitute therapeutic duplication.
• Diagnosis confirmation: ATTR-CM documentation (imaging, biopsy, or genetic testing) confirming the distinct disease being treated.

## Criteria-Mapping Structure

Your appeal letter should be direct: identify the alleged duplicate by name, state its mechanism and approved indication, then state tafamidis's mechanism and approved indication. A two-row table accomplishes this efficiently. Attach the relevant FDA label sections for both drugs. For duplicate-therapy denials, a focused, well-sourced one-page letter typically resolves the issue faster than a lengthy narrative.